The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement

QJM: An International Journal of Medicine

Volumn 91, Issue 2, 1998, Pages 141-157

  Dubrey, S W ^a,b   Cha, K ^a   Anderson, J ^a   Chamarthi, B ^a   Reisinger, J ^a   Skinner, M ^a   Falk, R H ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HAREFIELD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN LIGHT CHAIN; PROTEIN;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; DISEASE PREDISPOSITION; ECCHYMOSIS; ECHOCARDIOGRAPHY; FATIGUE; FEMALE; HEART AMYLOIDOSIS; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE WALL; HEART SIZE; HUMAN; HUMAN TISSUE; MACROGLOSSIA; MAJOR CLINICAL STUDY; MALABSORPTION; MALE; MULTIPLE ORGAN FAILURE; MUSCLE WEAKNESS; ONSET AGE; ORBIT; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RACE DIFFERENCE; SIGNAL AVERAGED ELECTROCARDIOGRAPHY; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 0031913337     PISSN: 00335622     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/91.2.141     Document Type: Article

References (47)

1. Simms RW, Prout MN, Cohen AS. The epidemiology of AL and AA amyloidosis. Balliere's Clin Rheumatol 1994; 8:627-34.
2. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995; 32:45-59.
3. Appleton CP, Hatle LK, Popp RL. Demonstration of restrictive ventricular physiology by Doppler echocardiography. J Am Coll Cardiol 1988; 11:757-68.
4. Kyle RA, Greipp PR. Amyloidosis (AL): Clinical and laboratory features in 229 cases. Mayo Clin Proc 1983; 58:665-83.
5. Roberts WC, Waller BF. Cardiac amyloidosis causing cardiac dysfunction: analysis of 54 necropsy patients. Am J Cardiol 1983; 52:137-46.
6. Smith TJ, Kyle RA, Lie JT. Clinical significance of histopathological patterns of cardiac amyloidosis. Mayo Clin Proc 1984; 59:547-55.
7. Siqueiro-Filho AC, Cunha CLP, Tajik AJ, Seward JB, Schattenberg TT, Giuliani ER. M-mode and two-dimensional echocardiographic features in cardiac amyloidosis. Circulation 1981; 63:188-96.
8. Cueto-Garcia L, Reeder GS, Kyle RA, Wood DL, Seward JB, Naessens J, Offord KP, Greipp PR, Edwards WD, Tajik AJ. Echocardiographic findings in systemic amyloidosis: spectrum of cardiac involvement and relation to survival. J Am Coll Cardiol 1985; 6:737-43.
9. Hamer JPM, Janssen S, Van Rijswijk MH, Lie KI. Amyloid cardiomyopathy in systemic non-hereditary amyloidosis. Clinical, echocardiographic and electrocardiographic findings in 30 patients with AA and 24 patients with AL amyloidosis. Eur Heart J 1992; 13:623-7.
10. Berg AM, Anderson JJ, Chipkin SR, Lee VK, Skinner M, Cohen AS, Simms RW. Autonomic neuropathy in AL (primary) amyloidosis and its effect on survival. Amyloid Int J Exp Clin Invest 1994; 1:39-46.
11. Carroll JD, Gaasch WH, McAdam KPWJ. Amyloid cardiomyopathy: characterisation by a distinctive voltage mass relation. Am J Cardiol 1982; 49:9-13.
12. Bazett HC. An analysis of the time relations of electrocardiograms. Heart 1920; 7:352-70.
13. Moss AJ. Measurement of the QT interval and the risk associated with QTc interval prolongation: a review. Am J Cardiol 1993; 72:23B-5B.
14. Falk RH. Cardiac amyloidosis. Progress Cardiol 1989; 2:143-5.
15. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57:450-8.
16. Sahn DJ, DeMaria A, Kisslo J, Weyman A. The Committee on M-mode standardizations of the American Society of Echocardiography: recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58:1072-83.
17. Charurvedi N, Athanassopoulos C, McKeigue P, Marmot MG, Nihoyannopoulos P. Echocardiographic measures of left ventricular structure and their relation with rest and ambulatory blood pressure in blacks and whites in the United Kingdom. J Am Coll Cardiol 1994; 24:1499-505.
18. Poll DS, Marchlinski FE, Falcone RA, Josephson ME, Simson MB. Abnormal signal-averaged electrocardiograms in patients with non-ischemic congestive cardiomyopathy: relationship to sustained ventricular tachyarrhythmias. Circulation 1985; 72:1308-13.
19. Hilton TC, Greenwalt T, Gudipati CV, Pearson AC, Buckingham TA. Effects of left ventricular hypertrophy on the signal-averaged electrocardiogram. Am J Cardiol 1990; 66:764-6.
20. Cohen AS, Rubinow A, Anderson JJ, et al. Survival of patients with primary (AL) amyloidosis and the effect of colchicine treatment: cases treated with colchicine from 1976-1983 compared with cases seen in previous years. Am J Med 1987; 82:1182-90.
21. Skinner M, Anderson JJ, Simms R, Falk R, Ming Wang MS, Libbey CA, Jones LA, Cohen AS. Treatment of 100 patients with primary (AL) amyloidosis: a randomized trial of melphalan, prednisone, and colchicine Vs Colchicine. Am J Med 1996; 100:290-8.
22. Comenzo RL, Vosburgh E, Simms RW, Bergethon P, Sarnacki D, Finn K, Dubrey S, Faller DV, Wright DC, Falk RH, Skinner M. Dose-intensive melphalan with blood stem-cell support for the treatment of AL amyloidosis: one year follow up in five patients, Blood 1996; 88:2801-6.
23. Dubrey S, Simms RW, Skinner M, Falk R. Recurrence of primary (AL) amyloidosis in a transplanted heart with four-year survival. Am J Cardiol 1995; 76:739-41.
24. McHenry LC Jr, Gazekas JS, Sullivan JF. Cerebral hemodynamics of syncope. Am J Med Sci 1961; 241:173-8.
25. Chamarthi B, Dubrey S, Cha K, Skinner M, Falk RH. Exertional syncope in restrictive cardiomyopathy - a common and ominous symptom in cardiac amyloidosis. Am J Cardiol 1997; in Press.
26. Ciro E, Nichol P, Maron B. Heterogeneous morphological expression of genetically transmitted hypertrophic cardiomyopathy. Two dimensional echocardiographic analysis. Circulation 1983; 67:1227-33.
27. Shapiro LM, McKenna WJ. Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy; a two-dimensional echocardiographic study. J Am Coll Cardiol 1983; 2:437-44.
28. Falk RH, Plehn JF, Deering T, Schick EC, Boinay P, Rubinow A, Skinner M, Cohen AS. Sensitivity and specificity of the echocardiographic features of cardiac amyloidosis. Am J Cardiol 1987; 59:418-22.
29. Dubrey S, Pollak A, Skinner M, Falk RH. Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis; evidence for atrial electro-mechanical dissociation. Br Heart J 1995; 74:541-4.
30. Dubrey S, Bilazarian S, LaValley M, Skinner M, Falk RH. Signal averaged electrocardiography in primary (AL) amyloidosis. Am Heart J 1997; in press.
31. Rosahn PD. Weight of normal heart in adult males. Yale J Biol Med 1941; 14:209-16.
32. Zeek PM. Heart weight: weight of normal human heart. Arch Pathol 1942; 34:820-32.
33. Dubrey S, Mendes L, Skinner M, Falk RH. Resolution of heart failure in patients with AL amyloidosis. Ann Intern Med 1996; 125:481-4.
34. Patel RA, Dubrey SW, Mendes LA, Skinner M, Cupples A, Falk RH, Davidoff R. Right ventricular dilatation in AL amyloidosis: an independent predictor of survival. Am J Cardiol 1997; 80:486-92.
35. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997; 337:898-909.
36. Merlini C. Treatment of primary amyloidosis. Semin Hematol 1995; 32:60-79.
37. 123I-labelled serum amyloid P component. N Engl J Med 1990; 323:508-13.
38. Parthenakis FI, Vardas PE, Ralidis L, Dritsas A, Nihoyannopoulos P. QT interval in cardiac amyloidosis. Clin Cardiol 1996; 19:51-4.
39. Brandt KD, Cathcart ES, Cohen AS. A clinical analysis of the course and prognosis of 42 patients with amyloidosis. Am J Med 1968; 44:955-69.
40. Bergsagel D. The incidence and epidemiology of plasma cell neoplasms. Stem Cells 1995: 13:1-9.
41. Wright JR, Calkins E. Clinical-pathologic differentiation of common amyloid syndromes. Medicine 1981; 60:429-47.
42. Moreau P, Milpied N, de Faucal P, Petit T, Herbouiller P, Bataille R, et al. High dose melphalan and autologous bone marrow transplantation for systemic amyloidosis with cardiac involvement. Blood 1996; 87:3063-4.
43. Dubrey S, Comenzo R, Ray P, Skinner M, Falk RH. Improvement of echocardiographic and electrocardiographic features in AL cardiac amyloidosis with intensive melphalan and autologous stem cell rescue. Circulation 1996; 94:270.
44. Kyle RA, Greipp PR. Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo. Blood 1978; 52:818-27.
45. Buxbaum JN, Hurley ME, Chuba J, Spiro T. Amyloidosis of the AL type: clinical, morphologic and biochemical aspects of the response to therapy with alkylating agents and prednisone. Am J Med 1979; 67:867-78.
46. Gertz MA, Kyle RA, Greipp PR. Response rates and survival in primary systemic amyloidosis. Blood 1991; 77:257-62.
47. Hawkins PN. The diagnosis, natural history and treatment of amyloidosis. J Roy Coll Phys 1997; 31:552-60.